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Abstract 1 
Background: Heroin smokers have high rates of chronic obstructive pulmonary disease 2 
(COPD), respiratory morbidity, hospital admission and mortality. We assessed the natural 3 
history of symptoms and lung function in this population over time. 4 
Methods: A cohort of heroin smokers with COPD was followed for 18-24 months. At 5 
baseline and follow-up, respiratory symptoms were measured by Medical Research Council 6 
Dyspnoea Scale (MRC) and COPD Assessment Tool (CAT), and post-bronchodilator 7 
spirometry was performed. Frequency of healthcare-seeking episodes was extracted from 8 
routine health records. Parametric, non-parametric and linear regression models were used 9 
to analyse the change in symptoms and lung function over time.  10 
Results: Of 372 participants originally recruited, 161 were assessed at follow-up (mean age 11 
51.0 [SD 5.3], 74 [46%] female) and 106 participants completed post bronchodilator 12 
spirometry. All participants were current or previous heroin smokers and 122 (75.8%) had 13 
smoked crack. Symptoms increased over time (MRC score by 0.48/year (p<0.001) and CAT 14 
score by 1.60/year (p<0.001). Forced expiratory volume in 1 second (FEV1) declined annually 15 
by 90ml (SD 190, p<0.001). This deterioration was not associated with change in tobacco or 16 
heroin smoking status or use of inhaled medications.  17 
Conclusion: Heroin smokers experience a high and increasing burden of chronic respiratory 18 
symptoms, and a decline in FEV1 that exceeds the normal age-related decline observed 19 
amongst tobacco smokers with COPD and healthy non-smokers. Targeted COPD diagnostic 20 
and treatment services hosted within opiate substitution services could benefit this 21 
vulnerable, relatively inaccessible, and underserved group of people 22 
Words 242/250 23 
24 
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Introduction 1 
Illicit drug use is common, with 8.5% of adults in England and Wales having reported taking 2 
an illicit drug in 2016/2017 [1].  Over the last thirty years smoking rather than injecting 3 
heroin has become more common [2-6]. In recent years smoking heroin rather than 4 
injecting has been used as a possible method of harm reduction[7, 8] .    5 
Although the effects of illicit drug use are well documented, there is limited evidence about 6 
the chronic effects of inhaled illicit drug use on the respiratory system.  Multiple case 7 
reports highlight acute asthma attacks in heroin users, and observational studies report a 8 
high prevalence of respiratory disease in heroin users admitted to acute hospitals [9, 10]. 9 
Severe early onset emphysema associated with premature mortality has been reported 10 
among heroin users [11-13]. However large-scale diagnostic studies in this hard-to-reach 11 
population are lacking. Chronic respiratory symptoms are common in those inhaling heroin, 12 
yet access to formal diagnosis including lung function measurement is limited [14-16]. 13 
We recently reported post bronchodilator spirometry in 703 heroin smokers attending for 14 
opiate substitution therapy (OST) at community drug service clinics in Liverpool; 50% of 15 
heroin smokers had either COPD or COPD-asthma overlap (ACO) despite a mean age of 47 16 
years [17]. This was associated with extensive respiratory symptoms, which given the known 17 
high rates of COPD hospitalisation and a continuing trend towards inhalation as the mode of 18 
drug use is likely to put increased burden on health systems [4, 6, 18].  In light of this, 19 
screening and treatment programmes for heroin smokers could be a viable method for 20 
identifying and treating disease in this relatively inaccessible patient group [19]. 21 
We performed a longitudinal cohort study of heroin smokers  attending community drug 22 
services and who were recruited as an original cohort of 703 heroin smokers described in 23 
terms of baseline characteristics in our previous paper [17]. The aim was to ascertain their 24 
change in health status, respiratory symptoms and lung function over an 18-24 month 25 
period. 26 
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Methods 1 
Setting 2 
The study was performed in 31 community drug service clinics in Liverpool, UK. Clinics are 3 
run by Addaction, a large independent charity commissioned by the local city council public 4 
health department.  A keyworker who knew the client and who coordinated their OST 5 
worked with the study team in each clinic.  6 
Participants 7 
Participants were invited to take part if they had previously completed spirometry in the 8 
baseline screening project that took place between December 2015 and June 2016[17], 9 
were over the age of 18 years, and were still fully enrolled in Addaction’s service.  All 10 
participants were current or previous smokers of heroin and were currently or recently 11 
treated with methadone or buprenorphine.  Participants were given the study information 12 
prior to being booked for their regular appointment and were offered a study visit at their 13 
usual clinic. Those missing their usual appointment were offered another at a central venue. 14 
Written informed consent was obtained from all participants. 15 
Variables and Data Source 16 
Baseline data collection has been previously described [17]. In brief, participants completed 17 
a questionnaire detailing demographic data, and self-reported tobacco and illicit drug use. 18 
Oxygen saturations were measured, and pre-and post-bronchodilator spirometry was 19 
completed. 20 
At follow up participants completed a questionnaire which evaluated self-reporting 21 
medication prescriptions, health care access, and ongoing tobacco and illicit drug use. The 22 
index of multiple deprivation (IMD), which is an official geographic measure of relative 23 
deprivation in England was used a proxy of social-economic status [20]. Participants also 24 
completed the COPD assessment tool (CAT) [21] and the Medical Research Council (MRC) 25 
dyspnoea scale [22], and consented to allow review of 2 years of medical records for 26 
respiratory related diagnosis and prescriptions from primary care pharmacy records (EMIS), 27 
and hospital records where applicable.  28 
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Oxygen saturations were measured, and pre-and post-bronchodilator spirometry was 1 
performed on all participants who consented and did not have medical contraindications. 2 
Spirometry was performed by trained clinical staff and completed according to American 3 
Thoracic Society (ATS) guidelines [23]. All traces were double-reviewed for quality and 4 
grading by an experienced respiratory physician. As with the baseline survey, participants 5 
were asked not to take a short acting bronchodilator within 8 hours of visit or a long-acting 6 
bronchodilator within 24 hours. If they had taken a short acting inhaler, only post 7 
bronchodilator spirometry was recorded.  8 
Subjects were categorised based on original screening. A diagnosis of asthma was given if 9 
airflow obstruction (Forced Vital Capacity /Forced Vital Capacity (FEV1/FVC) ratio <0.7) was 10 
fully reversible to inhaled salbutamol i.e. either FEV1/FVC normalised or FEV1 increased by ≥ 11 
400ml, or if spirometry was normal but the participant had a prior physician diagnosis of 12 
asthma. Those with non-reversible airflow obstruction were characterised as COPD unless 13 
they had a prior physician diagnosis of asthma, in which case their condition was labelled 14 
asthma-COPD overlap (ACO). We report the lung function change of those participants who 15 
had been diagnosed with COPD or ACO at baseline, those with an asthma diagnosis were  16 
excluded [17]. 17 
All spirometry data was reported using the European Community for Steel and Coal 18 
reference ranges for consistency with prior work [24]. Abnormal spirometry was defined 19 
using Global Initiative for Chronic Obstructive Lung Disease (GOLD) [25].  Change in lung 20 
function was based on post-bronchodilator FEV1. 21 
Sample Size  22 
We aimed to follow up as many of the participants with COPD or ACO from baseline as 23 
possible.  24 
Statistical analysis  25 
Univariate analysis was carried out using descriptive statistics to explore the characteristics 26 
of the study populations. Paired t-tests and Wilcoxon sign rank tests (with bootstrapping to 27 
estimate the confidence interval of the difference) were used to assess change between the 28 
two time points. Time was used as a continuous variable to account for variation between 29 
follow ups dates and to calculate an annualised change). A linear regression model was used 30 
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to estimate the effect of potential factors (change in inhaled illicit drug use, change in 1 
tobacco smoking, change in inhaler use) on changes in FEV1 over time. Variables were 2 
selected for the model a priori based on clinical data which might have varied over the 3 
course of follow-up within an individual, specifically those which described changes in drug 4 
or medication use. The whole model is presented without variable elimination. Data were 5 
analysed using Stata version 14.2 statistical software and R version 3.4. Statistical 6 
significance was tested at the conventional 5% level.     7 
Ethics 8 
Ethical approval was gained from Health Research Authority (HRA) via the integrated 9 
Research Application System (IRAS) number: 235151 10 
11 
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Results 1 
A total of 372 participants had previous COPD or ACO and were eligible for inclusion. The 2 
study follow-up took place between December 2017 to April 2018. Baseline questionnaire 3 
and clinical data were collected from 161 participants; 109 were lost to follow up, 49 did not 4 
attend the follow up appointment, 26 declined at the appointment, 23 were medically unfit 5 
and 4 did not take part for other reasons. 106 completed post-bronchodilator spirometry at 6 
both baseline and follow-up to ATS standards. Those remaining (n=55) did not meet ATS 7 
standards (22), were medical unfit (3), died (1) or declined post-bronchodilator spirometry 8 
(29) (Figure 1). Compression of participants characteristics can be seen in table E1.     9 
The characteristics of the population are given in Table 1. Participants had a mean (SD) age 10 
of 51 (5.3) years, and 46 (28.6%) were female. The majority of participants were 11 
unemployed with high levels of socioeconomic deprivation (mean IMD score 51.5 is in the 12 
lowest quintile for the England). All participants were taking OST with 76 (47.2%) reporting 13 
current heroin use.  14 
The majority were both prescribed an inhaler and were collecting prescriptions (defined as 15 
at least 50% pick up rate), from a pharmacy 131 (81.4%). No inhalers were prescribed or 16 
collected for 21 (13.3%), and data were unavailable for 9 (5.5%). Of those where data were 17 
available 129 (84.9%), 88 (57.9%) and 78 (51.3%)  collected prescriptions for short-acting 18 
beta2-agonist (SABA), long acting anti-muscarinic (LAMA) and an inhaled corticosteroid/long 19 
acting beta 2 agonist combination, respectively (Figure 2). Three quarters had attended a 20 
primary care practitioner for respiratory complaints within the preceding two years, with 18 21 
(11%) requiring admission to hospital, staying for a mean 11.5 days. Those admitted to 22 
hospital were universally treated with bronchodilators, antibiotics and steroids, three 23 
participants were offered non-invasive ventilation, two were treated in high-dependency 24 
areas and none had level 3 care (invasive ventilation) (Table 2). 25 
The mean FEV1 was 2.05L (SD 0.96) at follow up compared to 2.23 (SD 0.97) at baseline. Of 26 
those diagnosed with COPD/ACO at baseline and post-bronchodilator spirometry at both 27 
time points, 94 (88.7%) had spirometry indicative of COPD at follow up , with 38 (35.9%) 28 
having severe or very severe COPD (using GOLD guidelines) at follow-up compared to 26 29 
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(24.6%) at baseline. A further 5 (4.7%) had full reversibility (over 400 ml) and therefore were 1 
diagnosed with asthma and 7 (6.6%) had normal spirometry at follow up (Table 3). 2 
Participants reported a significant annualised increase in respiratory symptoms with the 3 
MRC and CAT scores increasing by a median of 0.48 (p<0.001) and 1.60 (p<0.001), 4 
respectively. They experienced a significant annualised decline in FEV1 and median oxygen 5 
saturation of 90ml (p<0.001) and 0.92% (p<0.001), respectively (table 4). Change in smoking 6 
status and inhalers use were pre-hypothesised possible clinical factors that could influence 7 
FEV1 change. Since baseline, 49 (31.2%) participants reported a decrease in heroin smoking, 8 
and 73 (46.5%) reporting an unchanged usage (Figure 3). Change in drug use was not 9 
associated with change in FEV1. The final model showing change in drug and tobacco 10 
smoking status and inhaler use is presented in Table 5 11 
Discussion 12 
In a population of heroin smokers we found a high burden of lung disease. In the previously 13 
published baseline data 50% of heroin users had COPD or ACO, with a mean MRC of 3.1 and 14 
CAT score of 22.9 [17]. At follow-up participants’ respiratory symptoms had worsened 15 
significantly from baseline, with annual increases in both CAT score (1.60) and MRC score 16 
(0.46), and mean oxygen saturation dropping from 97% to 95% from baseline to follow up. 17 
We found that lung function measured by FEV1 declined by 90ml annually, which was both 18 
statistically and clinically significant. The proportion of subjects classified as having severe or 19 
very severe disease with this rising from 25% to 36% over the 2-year follow up period. 20 
Neither ongoing illicit drug use nor prescriptions of inhaled medication were associated with 21 
change in lung function.  22 
The symptoms reported in this study are consistent with those of studies in this population, 23 
with increased dyspnoea amongst heroin users being the common symptom [12, 13, 27]. 24 
The decline in health status measured by a CAT score increase of 1.60 annually, is greater 25 
than 1 unit change seen in stable COPD patients[26] . The rate of decline in FEV1 is 26 
considerably higher than both the 30ml/year age-related decline seen in non-smokers and 27 
in people with tobacco-related COPD (which is reported at 35-79ml per year, of which all 28 
but one paper reported an annual decline of 69ml or less) [27, 28].  To date research on lung 29 
function in heroin smokers has focused on cross-sectional studies. The results from this 30 
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longitudinal cohort study support and enhance previous cross-sectional studies that 1 
suggested heroin users are at a high risk of COPD and suggests that their decline is worse 2 
than that of tobacco smokers. Walker et al found heroin smokers developed early onset 3 
emphysema, with a mean age of diagnosis being 41 years, suggesting likely early 4 
progression of disease compared to non-heroin smokers [11]. In Amsterdam, Buster et al 5 
reported difference in FEV1 from predicted values, finding that heroin smokers had a FEV1 of 6 
260ml less than predicted FEV1 [14].  7 
The rapid decline in FEV1 and the increase in respiratory symptoms in this population 8 
suggests heroin smoking is a driver of decline in lung function. Similarly, once established 9 
this decline appears to continue even in those who stop smoking drugs.   10 
Although COPD hospital admissions vary greatly across the UK, those with COPD tend to 11 
have high health care usage, particularly in areas of high deprivation [29, 30]. Previous 12 
research has also shown that heroin users with respiratory exacerbations are more likely to 13 
be readmitted with exacerbations than current / ex-tobacco smokers (OR: 1.00 versus 14 
0.22/0.26) [18]. It is also clear that with high levels of health care access observed in this 15 
population,  it is likely that ongoing trends towards inhaling heroin will further increase the 16 
use of, and burden on, the health system [4, 6].  17 
Strengths of our study include that we followed up the participants over a 18-24 month 18 
period, in a community clinic setting. We have shown that it is feasible to engage this client 19 
group in both baseline and follow up spirometry allowing for a diagnosis to be made. The 20 
lost to follow up rate is a major limitation of this study, reducing the power of statistical 21 
analysis and makes stratification of our results by age or GOLD stage unfeasible. Given a 22 
larger group, this information would potentially be helpful for targeting care, and is an area 23 
for future investigation. This population smoke a mix of heroin, crack and tobacco, 24 
establishing a causal relationship with therefore difficult. The participants in the study were 25 
generally from a poor socio-economic background, and there is potential that their living 26 
condition environment could contribute to the rate of decline. Without significant 27 
heterogeneity of such potentially confounding factors, we have been unable to address this 28 
question further. There is also potential for selection bias, with those who regularly attend 29 
methadone clinics and have concerns about their respiratory system more likely to 30 
participate in the study.    31 
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In summary, our findings show the significant respiratory impairment with which heroin 1 
smoking is implicated, and a concerning accelerated rate of decline over time. Future 2 
studies with larger cohorts, possibly in the context of a targeted public health intervention, 3 
are needed to understand if specific sub-groups are especially vulnerable, and how the 4 
personal and healthcare costs associated with chronic respiratory illness could be best 5 
averted. The study methodology is in support of it being feasible to co-locate respiratory 6 
and drug services to one community location. Future studies may benefit from a parallel 7 
group of heroin users without spirometric abnormalities at baseline to determine their rate 8 
decline compared to those with COPD. These results combined with previous studies 9 
support the call for enhanced screening for inhaled drug users [19].  A pilot followed by 10 
clinical trial would be needed to assess if screening and treatment services would be 11 
clinically and cost effective in this population.  12 
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Table 1 1 
 n=161 
Sex, n female (%) 46 (28.6) 
Age in years, mean (SD) 51.0 (5.3) 
IMD Score 51.5 (12.7) 
Occupation 
Unemployed, n (%) 137 (85.1) 
Employment, n (%) 24 (14.9) 
Housing 
Own home (including rented), n 
(%) 
124 (77.0) 
Homeless, n (%) 6 (3.7) 
Other, n (%) 31 (19.3) 
Cigarette Smoking Status 
Current, n (%) 133 (82.6) 
Ex, n (%) 27 (16.8) 
Never, n (%) 1 (0.6) 
Cigarettes smoked per day/ SD 11 (7.0) 
Heroin Smoking Status 
Current, n (%) 76 (47.2) 
Ex, n (%) 85 (52.8) 
Bags smoked per week*, n (SD) 4.0 (7.0) 
Crack smoking  
Current, n (%) 33 (20.5) 
Ex, n (%) 89 (55.3) 
Never, n (%) 39 (24.2) 
Rocks smoked per week, n (SD) 2.18 (1.4) 
Cannabis Smoking Status 
Current, n (%) 38 (23.8) 
Ex, n (%) 53 (33.1) 
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Never, n (%) 69 (43.1) 
Cannabis joint per week, n (SD) 12 (17.1) 
Ever injected Heroin, n (%) 30 (18.5) 
Current Methadone dosage, mean 
mL/day (SD) 
45.7 (21.6) 
Current buprenorphine dosage, 
mean mg/day (SD) 
10.4 (8.8) 
 1 
Table legend 2 
Characteristics of those 161 people with baseline COPD or ACO derived from  follow up 3 
questionnaire data. * a bag is esimated to equate to 0.1g 4 
  5 
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Table 2 1 
 n=161 
Taking an inhaler regularly  
 Yes, n (%) 131 (81.4) 
 No, n (%) 21 (13.0) 
 Not  known, n (%) 9 (5.6) 
Reported GP visits in last 2 years for respiratory conditions 
 Yes, n (%) 121 (75.2) 
 No, n (%) 25 (15.5) 
 Not known, n (%) 15 (9.3) 
Number Primary care visit (GP or Nurse), mean 
(SD) 
8.6 (7.0) 
Emergency hospital visits for respiratory conditions 
 Yes, n (%) 17 (10.6) 
 No, n (%) 114 (70.8) 
 Not known, n (%) 30 (18.6) 
Emergency hospital visits of those who did 
attend, mean (SD) 
2.6 (1.9) 
Admitted to hospital in last 2 years for respiratory conditions 
 Yes, n (%) 17 (10.5) 
 No, n (%) 121(74.7) 
 Not known, n (%) 24 (14.8) 
Length of hospital stay, mean days (SD) 11.5 (13.0) 
 2 
Table legend 3 
Healthcare utilisation from 2 years prior to follow up, amongst those who completed follow 4 
up questionnaires. Data was gathered from electronic medical records; participants not 5 
appearing on these systems are coded as “Not known”, but might engage with extra-6 
regional, informal or private healthcare providers. 7 
  8 
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Table 3 1 
 Baseline Follow up 
FEV1, mean L (SD) 2.23 (0.97) 2.05 (0.95) 
FEV1, % predicted (SD) 69.1 (2.6) 64.6 (2.7) 
FVC, mean L (SD) 4.07 (1.2) 3.69 (1.1) 
FVC, % predicted (SD) 102.7 (23.7) 95.5(23.4) 
FEV1/FVC, ratio (SD) 0.54 (0.13) 0.53 (0.14) 
Diagnosis (GOLD)   
 ACO, n (%) 4 (3.8) - 
 Asthma, n (%) - 5 (4.7) 
 Normal, n (%) - 7 (6.6) 
Severity (GOLD)   
 Mild, n (%) 37 (34.9) 23 (21.7) 
 Moderate, n (%) 39 (36.8) 33 (31.1) 
 Severe, n (%), n (%) 15 (14.2) 24 (22.7) 
 Very Severe, n (%) 11 (10.4) 14 (13.2) 
 2 
Table legend 3 
Diagnosis and post-bronchodilator spirometry at baseline and 2-year follow-up of the 106 4 
participants diagnosed with COPD or ACO at baseline who completed follow-up  5 
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Table 4 1 
Variable  Baseline Follow up Change per year Bootstrapping 
/CI 
p value   
FEV1 L, mean (SD) 2.23 (97.12) 2.05 (95.60) -0.09 (0.19) -0.05- -0.13 <0.001  
MRC Score, 
median (P25-
,P75) 
3 (2-4) 4 (3-5) 0.46 (0.0-1.0) 0.52 (0.36-
0.67) 
<0.001  
CAT Score, 
median (P25-P75) 
25 (17-31) 29 (23-33) 1.60 (-0.48-4.32) 0.46 (0.29-
0.60) 
<0.001 
SpO2 (%), median 
(P25-P75) 
97 (96-98) 95 (93-96) -0.92 (-1.63-0.0) 0.53 (0.38-
0.66) 
<0.001 
 2 
Table legend 3 
Annualised change in spirometry and symptoms in the 106 participants diagnosed with 4 
COPD or ACO at baseline who completed follow-up . FEV1 Force vital capacity in 1 second, 5 
MRC Medical Research Council Dyspnoea score, CAT COPD Assessment Test, SPO2 Peripheral 6 
Capillary Oxygen Saturation 7 
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Table 5 1 
 Coefficient (95% CI) 
for FEV1 decrease 
(ml/year) 
p-value (CI) 
Change in reported heroin 
consumption 
  
 No change  Ref  
 Increase* 5.92 0.36 (-3.46-15.31) 
 Decrease† 5.35 0.21 (-6.31-17.03) 
Change in reported crack consumption   
 No change  Ref  
 Increase* 0.18 0.96 (-9.00-7.68) 
 Decrease† 2.69 0.69 (-10.55-15.94) 
Change in tobacco consumption   
 No change  Ref  
 Increase* 7.81 0.80 (-9.91-7.68) 
 Decrease† -1.11 0.34 (-8.51-24.14) 
Change in inhaler use   
 No change    
 Increase* -3.20 0.48 (-12.12-5.72) 
 Decrease† 1.79 0.79 (-11.61-15.20) 
 2 
Table legend 3 
Linear Regression Model of post bronchodilator FEV1 change (n=106). *A positive change is 4 
an increase in use since baseline, † A negative change is a decrease in usage since baseline. 5 
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Figure 1 1 
 2 
Figure legend 3 
Flow of participants through the study 4 
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Figure 2 1 
 2 
Figure legend 3 
Participants prescribed and picking up their inhalers (at least 50% of what was expected as 4 
recorded by the pharmacy team) as recorded on the primary care electronic prescribing 5 
system. Inhalers reviewed were Short Acting Beta2 Agonist (SABA), Long Acting Beta2 6 
Agonist (LABA), Long Acting Anti-Muscarinic (LAMA) and Inhaled Corticosteroid (ICS). 7 
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Figure 3 1 
 2 
 Figure legend 3 
Change in daily consumption of tobacco, heroin and crack in 161 subjects over 2 years. If 4 
they have never smoked their smoking status was recorded as “stayed the same”.  5 
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Screening heroin smokers attending community drug 1 
clinics for change in lung function: A cohort study. 2 
Supplement 3 
 4 
Supplement Table E1: Characteristics of participants completing follow up questionnaires, 5 
with and without ATS standard spirometry 6 
 7 
Variable Acceptable 
spirometry 
N (%) 
Mean (SD) 
Unacceptable 
spirometry or 
declined/excluded 
for medical reasons 
N (%) 
Mean (SD) 
 
Chi2 or Ttest p-
value 
Sex N=106 N=55  
Female 30.2 (32) 25.5 (14) 0.53 
Male 69.8 (74) 74.5 (41) 
Age in years, mean 
(SD) 
50.9 (5.2) 51.3 (5.6) 0.67 
IMD Score 50.3 (12.9) 53.9 (12.3) 0.09 
Occupation   0.65 
Unemployed 85.9 (91) 83.6 (46) 
Employed 14.1 (15) 16.2 (9) 
Housing   0.76 
Own home 
(included rental),n 
77.4 (82) 76.4 (42) 
Homeless, n (%) 4.72 (5) 1.82 (1) 
Other, n (%) 17.9 (19) 21.78 (12) 
Cigarette Smoking 
Status 
  0.125 
Current , n (%) 78.3 (83) 50 (90.9) 
Ex, n (%) 22 (20.8) 5 (9.1) 
Never, n (%) 1 (0.9) 0 (0) 
Heroin Smoking 
Status 
  0.312 
Current, n (%) 44.34 (47) 52.7 (29) 
Ex, n(%) 55.7 (59) 47.3 (26) 
Crack smoking   0.74 
Current, n (%) 18.9 (20) 23.6 (13) 
Ex, n(%) 55.6 (59) 54.6 (30) 
Never, n (%) 25.5 (27) 21.8 (12) 
